Items tagged with Drug-resistant TB
Drug-resistant tuberculosis is a global crisis. Why are we doing so little to fight it? (post)
Here in the waiting room of Helen Joseph Hospital, a cough never sounds like just a cough. It’s more like the audio accompaniment for a glimpse at what may be the most sustained medical catastrophe of our time. A throng of new patients are spectral figures, the latest victims of what public-health officials dub a “co-epidemic” of tuberculosis and HIV. The patients’ off-white masks flutter whenever they break into that distinctive guttural bark, followed by a raspy rattle in the throat. Linger long enough in this room and you’ll hear prayers offered: “Please, Jesus, let this be a case of ordinary tuberculosis.” Rising numbers of patients are infected with strains of Mycobacterium tuberculosis resistant to commonly used medications. Treatment, then, will be longer, more punishing, and less effective.
New research traces origins of drug-resistant TB to the 1950s in KZN (post)
The emergence of drug resistance is threatening the control of tuberculosis in South Africa and other parts of the world. Researchers from K-RITH and the Broad Institute of MIT and Harvard have traced the roots of extensively drug-resistant TB (XDR TB) in KwaZulu-Natal (KZN) to the late 1950s. Their findings, published in the journal PLOS Medicine, have vital implications for the way we understand how XDR strains are spread, and the management and treatment of TB in South Africa and elsewhere in the world.
Towards genomic prediction of drug resistance in tuberculosis (post)
In 2014, WHO approved a new strategy for the elimination of tuberculosis,1 and recommended that countries adapt the strategy's pillars—patient-centred care, supportive systems, and innovation—as appropriate to their local contexts. The need for a novel approach to elimination of tuberculosis in low-incidence settings was further echoed in a second framework2 that laid out eight priority areas. Among the prescribed interventions were investment in new technologies and rapid drug-susceptibility testing to optimise treatments. In The Lancet Infectious Diseases, Timothy Walker and colleagues3 present an important study at the nexus of these areas, establishing a foundation for routine use of whole-genome sequencing in the mycobacteriology laboratory.
This disease could kill 75 million people by 2050 (post)
The White House has a plan to combat multidrug-resistant tuberculosis, but it may never get funded.
USAID to reach patients in more than 100 countries with life-saving medicine for drug-resistant tuberculosis (post)
Patients in Georgia suffering from deadly strains of multidrug-resistant tuberculosis (MDR-TB) will soon have access to potentially life-saving medication thanks to a collaboration between the U.S. Agency for International Development (USAID) and Janssen. Nearly 200 patients in Georgia will begin receiving the tuberculosis drug, SIRTURO® (bedaquiline), as part of their treatment program for MDR-TB. Georgia is classified as a high MDR-TB burden country with 48 percent of known TB cases being identified as multidrug-resistant.
Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India (post)
Abstract
Webinar: “A global update on the use of bedaquiline for programmatic management of drug-resistant tuberculosis” (post)
In the “Implementation Innovations” webinar series from USAID and SIAPS, Dr. Jennifer Furin presented on September 10, 2015 about new TB drug bedaquiline. This webinar provided up-to-date information on the use of bedaquiline for treatment of patients under program conditions. This webinar may be of special interest to consultants, program managers, and clinicians working in the field of drug-resistant TB.
Webinar: “A global update on the use of delamanid for programmatic management of drug-resistant tuberculosis” (post)
In the “Implementation Innovations” webinar series from USAID and SIAPS, Dr. Jennifer Furin and Dr. Gunta Dravniece presented on October 13, 2015 about new TB drug delamanid. This webinar provided up-to-date information on the use of delamanid for treatment of patients under program conditions. This webinar may be of special interest to consultants, program managers, and clinicians working in the field of drug-resistant TB.
MSF: Global TB report reveals rate of diagnosis for MDR-TB cases is heading in the wrong direction (post)
According to the World Health Organization’s World tuberculosis report 2015, released 28 October, only one in four (26%) of the 480,000 people estimated to have developed multidrug-resistant TB (MDR-TB) in 2014 was diagnosed. Worse, the total number of people diagnosed with MDR-TB globally in 2014 was actually lower than the previous year (123,000 in 2014 vs 136,000 in 2013), although the total estimated number of people who developed MDR-TB remained the same. In 2014, only 58% of previously treated MDR-TB cases were tested for drug resistance; while this marks an improvement over 2013’s rate of 17%, it’s far from the 100% target set for 2015 in the Global Plan to Stop TB (2011-2015). While the number of people put on MDR-TB treatment increased slightly from 97,000 in 2013 to 111,000 in 2014, the cure rate remains desperately low at 50%.
RESIST-TB Clinical Trials Progress Report: clinical trials for drug-resistant TB (post)
Visit the RESIST-TB Clinical Trials Progress Report to check out what trials are in development, enrolling and completed. The Clinical Trials Progress Report is available as a PDF here.
Page 20 of 117 · Total posts: 0
←First 19 20 21 Last→